Effect of Donor Diabetes and Other Factors on Corneal Transplant Endothelial Cell Loss and Success at 5 Years

NCT ID: NCT07217249

Last Updated: 2025-12-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

570 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-03

Study Completion Date

2030-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This multi-center clinical trial is designed to assess the association of diabetes in a cornea donor with transplant success and loss of endothelial cells 5 years following Descemet membrane endothelial keratoplasty (DMEK). Study eyes are assigned to receive either a cornea from a donor without diabetes or a cornea from a donor with diabetes in a masked fashion.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fuchs Endothelial Corneal Dystrophy Corneal Endothelial Decompensation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Assigned cornea from a donor without diabetes

Eyes assigned to this arm receive a cornea from a donor without diabetes and undergo Descemet membrane endothelial keratoplasty.

Group Type ACTIVE_COMPARATOR

Descemet membrane endothelial keratoplasty

Intervention Type PROCEDURE

Replacement of the recipient corneal endothelial and Descemet membrane with healthy tissue from a donor cornea.

Assigned cornea from a donor with diabetes

Eyes assigned to this arm receive a cornea from a donor with diabetes for Descemet membrane endothelial keratoplasty.

Group Type ACTIVE_COMPARATOR

Descemet membrane endothelial keratoplasty

Intervention Type PROCEDURE

Replacement of the recipient corneal endothelial and Descemet membrane with healthy tissue from a donor cornea.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Descemet membrane endothelial keratoplasty

Replacement of the recipient corneal endothelial and Descemet membrane with healthy tissue from a donor cornea.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Willing to return to the study site for follow up at 3 and 5 years after a Descemet membrane endothelial keratoplasty procedure
* Fluent in English or Spanish
* Willing to have fingerstick blood sample collected to determine HbA1c level
* Participated and completed 12-month follow-up in the DEKS study for one or both eyes or a DEKS participant that had a study eye regraft prior to the 12-month visit.

Exclusion Criteria

* Lack cognitive capacity such that consent could not be provided.
Minimum Eligible Age

30 Years

Maximum Eligible Age

93 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Eye Institute (NEI)

NIH

Sponsor Role collaborator

Case Western Reserve University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jonathan Lass, MD

Role: PRINCIPAL_INVESTIGATOR

Case Western Reserve University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Price Vision Group

Indianapolis, Indiana, United States

Site Status RECRUITING

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States

Site Status NOT_YET_RECRUITING

University of Michigan/Kellogg Eye Center

Ann Arbor, Michigan, United States

Site Status NOT_YET_RECRUITING

Verdier Eye Center

Grand Rapids, Michigan, United States

Site Status RECRUITING

Mayo Clinic

Rochester, Minnesota, United States

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jonathan Lass, MD

Role: CONTACT

216-844-8608

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Marianne Price, PhD

Role: primary

317-814-2990

Constance Mullinix

Role: primary

319-356-2861

Munira Hussain

Role: primary

734-647-8397

Paula Johnson

Role: primary

616-949-2001

Diane Vogen

Role: primary

507-538-8119

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1UG1EY037206-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

5UG1EY030030-05

Identifier Type: NIH

Identifier Source: secondary_id

View Link

DEKS 5-year Extension Study

Identifier Type: -

Identifier Source: org_study_id